Acquisition by Bentsur Ron of 4500 shares of Nuvectis Pharma at 4.65 subject to Rule 16b-3
| NVCT Stock | USD 5.58 0.19 3.53% |
Slightly above 55% of Nuvectis Pharma's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Nuvectis Pharma suggests that some traders are interested. Nuvectis Pharma's investing sentiment can be driven by a variety of factors including economic data, Nuvectis Pharma's earnings reports, geopolitical events, and overall market trends.
Nuvectis |
Filed transaction by Nuvectis Pharma Director, 10 Percent Owner, Officer: Chairman & Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Nuvectis Pharma Fundamental Analysis
We analyze Nuvectis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvectis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvectis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Nuvectis Pharma is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Nuvectis Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nuvectis Pharma stock to make a market-neutral strategy. Peer analysis of Nuvectis Pharma could also be used in its relative valuation, which is a method of valuing Nuvectis Pharma by comparing valuation metrics with similar companies.
Peers
Nuvectis Pharma Related Equities
| CMPX | Compass Therapeutics | 11.43 | ||||
| HOWL | Werewolf Therapeutics | 7.69 | ||||
| OBIO | Orchestra BioMed | 7.62 | ||||
| CCCC | C4 Therapeutics | 7.10 | ||||
| OLMA | Olema Pharmaceuticals | 5.75 | ||||
| GOSS | Gossamer Bio | 5.15 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.43 | ||||
| LRMR | Larimar Therapeutics | 4.24 | ||||
| CELC | Celcuity LLC | 3.73 | ||||
| KRON | Kronos Bio | 3.09 | ||||
| EWTX | Edgewise Therapeutics | 2.55 | ||||
| IKNA | Ikena Oncology | 2.42 | ||||
| CGEM | Cullinan Oncology | 2.34 | ||||
| IVA | Inventiva | 0.93 | ||||
| GLUE | Monte Rosa | 0.84 | ||||
| REPL | Replimune | 0.48 | ||||
| NAMS | NewAmsterdam Pharma | 0.08 | ||||
| AVTE | Aerovate Therapeutics | 0.37 | ||||
| CNTA | Centessa Pharmaceuticals | 2.80 | ||||
| LYRA | Lyra Therapeutics | 4.55 |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.